Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Intercontinental Exchange to Acquire Trayport from BGC Partners and GFI for $650 Million in Stock
-
BGC and GFI Announce Agreement to Sell Trayport to Intercontinental Exchange for $650 Million
-
Alcobra Ltd. (ADHD) Prices 6.18M Ordinary Stock Offering at $6.50/Share
-
Alcobra Ltd. Prices Public Offering of Ordinary Shares
-
Alcobra Ltd. Prices Public Offering of Ordinary Shares
-
Nanotech to Present at Cantor Fitzgerald's 4th Annual Growth Conference
-
Signal Genetics Highlights Recent Achievements and Reports Third Quarter 2015 Financial Results
-
Signal Genetics Highlights Recent Achievements and Reports Third Quarter 2015 Financial Results
-
Ophthalmology Innovation Summit Gives Nod to Successful Public Start-ups
-
Agility Health to Present at Cantor Fitzgerald Canada - 4th Annual Growth Conference
-
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2015 Financial Results
-
Lucera and Perseus Launch First Global On-Demand SDN Financial Network Exclusively for Capital Markets
-
Orchid Island Capital Announces November 2015 Monthly Dividend and October 30, 2015 RMBS Portfolio Characteristics
-
Notable Analyst Rating Changes 11/10: (RIO) (PGRE) (HRZN) Upgraded; (CYBR) (FL) (ACI) Downgraded
-
WiLAN to Present at Cantor Fitzgerald Canada's 4th Annual Growth Conference
-
Magnum Hunter Resources (MHR) Shares Pressured Following 10-Q Filing
-
Norsat to Present at Cantor Fitzgerald's 4th Annual Growth Conference
-
Cantor Fitzgerald Starts Verisk Analytics (VRSK) at Buy
-
Cantor Fitzgerald Starts MSCI Inc. (MSCI) at Buy
-
Cantor Fitzgerald Starts IHS Inc. (IHS) at Hold
-
Cantor Fitzgerald Starts Advisory Board Company (ABCO) at Buy
-
Cantor Fitzgerald Starts Moody's Corp (MCO) at Hold
-
Cantor Fitzgerald Starts Corporate Executive Board (CEB) at Buy
-
Cantor Fitzgerald Starts FactSet Research Systems (FDS) at Hold
-
Cantor Fitzgerald Starts Gartner (IT) at Buy
-
Cantor Fitzgerald Starts McGraw Hill Financial (MHFI) at Buy
-
Energy XXI Reports Fiscal 2016 First quarter Results and Operations Update
-
After HomeAway, fewer options to bet directly on sharing economy
-
Cantor Fitzgerald Upgrades American Capital (ACAS) to Buy
-
Tetragon Financial Group Limited: PERFORMANCE REPORT FOR PERIOD ENDED 30 SEPTEMBER 2015
-
Sunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights
-
Notable Analyst Rating Changes 11/4: (NOK) (OCLR) (EVDY) Upgraded; (KMT) (AIG) (MNKD) Downgraded
-
Cantor Fitzgerald Starts Tonix Pharma (TNXP) at Buy
-
Cantor Fitzgerald Starts Flexion Therapeutics (FLXN) at Buy
-
Cantor Fitzgerald Starts Egalet Ltd (EGLT) at Buy
-
Cantor Fitzgerald Starts DepoMed Inc (DEPO) at Buy
-
Cantor Fitzgerald Starts Cara Therapeutics (CARA) at Buy
-
Cantor Fitzgerald Starts BioDelivery Sciences International (BDSI) at Buy
-
Cantor Fitzgerald Starts Culp, Inc. (CFI) at Hold
-
Adam Futterman Joins LEERINK Partners Institutional Equities Team
-
Roka Bioscience (ROKA) Announces Controlled Equity Offering Sales Agreement
-
Cantor Fitzgerald Downgrades Aaron's (AAN) to Hold
-
Cantor Fitzgerald Upgrades Fluidigm Corporation (FLDM) to Buy
-
Orchid Island Capital Announces Third Quarter 2015 Results
-
Cytokinetics, Inc. Reports Third Quarter 2015 Financial Results
-
CIBL Announces Filing Of Its SPAC's Registration Statement
-
Rosetta Genomics Reports Financial Results for the First Half of 2015
-
Cantor Fitzgerald Starts Ignyta, Inc (RXDX) at Buy
-
Cantor Fitzgerald Starts Mirna, Inc. (MIRN) at Buy
-
Dimension Therapeutics (DMTX) IPO Opens Modestly Lower

